Helle D Zacho1, Michael Gade2, Jesper C Mortensen3, Henrik Bertelsen4, Søren K Boldsen5, Tamás Barsi6, Lars J Petersen7. 1. Department of Nuclear Medicine, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark; Department of Clinical Physiology, Viborg Hospital, Viborg, Denmark; Department of Clinical Medicine, Aalborg, University, Denmark, Aalborg, Denmark. Electronic address: h.zacho@rn.dk. 2. Department of Nuclear Medicine, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark. 3. Department of Nuclear Medicine, Regional Hospital West Jutland, Holstebro, Denmark. 4. Department of Nuclear Medicine, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark; Department of Clinical Physiology and Nuclear Medicine, Randers Hospital, Randers, Denmark. 5. Department of Clinical Medicine, Aalborg, University, Denmark, Aalborg, Denmark. 6. Department of Urology, Viborg Hospital, Viborg, Denmark. 7. Department of Nuclear Medicine, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark; Department of Clinical Medicine, Aalborg, University, Denmark, Aalborg, Denmark.
Abstract
OBJECTIVE: To prospectively determine the prognostic value of the bone scan index (BSI) for time to development of castration-resistant prostate cancer (CRPC) in consecutive, hormone-naïve patients with newly diagnosed prostate cancer. PATIENTS AND METHODS: Eligible patients participated in a prospective, observational, multicenter study of the value of bone scintigraphy (BS) at staging. BSI was determined using the EXINI BoneBSI software in 208 consecutive patients undergoing androgen deprivation therapy. The presence or absence of bone metastases at staging was classified by BS with or without supplementary imaging. Follow-up was performed >5 years after including the last patient. RESULTS: During follow-up, 149 of the 208 patients (72%) were diagnosed with CRPC. Median time to CRPC was 20 months. Median follow-up time was 4.4 years in patients without CRPC. In univariate analyses, presence of bone metastases (M1) (hazard ratio [HR] 3.00, 95% confidence interval [CI] 2.10-4.30), Gleason grade (HR 1.53, 95% CI 1.31-1.79), and BSI (HR 1.17, 95% CI 1.12-1.23) but not PSA significantly predicted time to CRPC (all, P < .001). The predictive values of M1 (HR 2.06), Gleason grade (HR 1.47), and BSI (HR 1.10) were confirmed in multivariate analyses. Log-rank test for equality of time to CRPC showed the significant predictive value of BSI (BSI = 0 vs 0 < BSI ≤ 1 vs BSI > 1, P < .001). In addition to routine assessment of M1 vs M0 status, BSI contributed to the predictive power. CONCLUSIONS: BSI is an independent risk factor for the time from initiation of androgen deprivation therapy to CRPC in hormone-naïve patients. The significant prognostic factors, in rank order, were M1 status, Gleason grade, and BSI.
OBJECTIVE: To prospectively determine the prognostic value of the bone scan index (BSI) for time to development of castration-resistant prostate cancer (CRPC) in consecutive, hormone-naïve patients with newly diagnosed prostate cancer. PATIENTS AND METHODS: Eligible patients participated in a prospective, observational, multicenter study of the value of bone scintigraphy (BS) at staging. BSI was determined using the EXINI BoneBSI software in 208 consecutive patients undergoing androgen deprivation therapy. The presence or absence of bone metastases at staging was classified by BS with or without supplementary imaging. Follow-up was performed >5 years after including the last patient. RESULTS: During follow-up, 149 of the 208 patients (72%) were diagnosed with CRPC. Median time to CRPC was 20 months. Median follow-up time was 4.4 years in patients without CRPC. In univariate analyses, presence of bone metastases (M1) (hazard ratio [HR] 3.00, 95% confidence interval [CI] 2.10-4.30), Gleason grade (HR 1.53, 95% CI 1.31-1.79), and BSI (HR 1.17, 95% CI 1.12-1.23) but not PSA significantly predicted time to CRPC (all, P < .001). The predictive values of M1 (HR 2.06), Gleason grade (HR 1.47), and BSI (HR 1.10) were confirmed in multivariate analyses. Log-rank test for equality of time to CRPC showed the significant predictive value of BSI (BSI = 0 vs 0 < BSI ≤ 1 vs BSI > 1, P < .001). In addition to routine assessment of M1 vs M0 status, BSI contributed to the predictive power. CONCLUSIONS: BSI is an independent risk factor for the time from initiation of androgen deprivation therapy to CRPC in hormone-naïve patients. The significant prognostic factors, in rank order, were M1 status, Gleason grade, and BSI.
Authors: Mike Wenzel; Felix Preisser; Benedikt Hoeh; Maria Schroeder; Christoph Würnschimmel; Thomas Steuber; Hans Heinzer; Severine Banek; Marit Ahrens; Andreas Becker; Pierre I Karakiewicz; Felix K H Chun; Luis A Kluth; Philipp Mandel Journal: Front Oncol Date: 2021-04-23 Impact factor: 6.244
Authors: Katharina Beyer; Lisa Moris; Michael Lardas; Anna Haire; Francesco Barletta; Simone Scuderi; Megan Molnar; Ronald Herrera; Abdul Rauf; Riccardo Campi; Isabella Greco; Kirill Shiranov; Saeed Dabestani; Thomas van den Broeck; Sujenthiran Arun; Mauro Gacci; Giorgio Gandaglia; Muhammad Imran Omar; Steven MacLennan; Monique J Roobol; Bahman Farahmand; Eleni Vradi; Zsuzsanna Devecseri; Alex Asiimwe; Jihong Zong; Sara J Maclennan; Laurence Collette; James NDow; Alberto Briganti; Anders Bjartell; Mieke Van Hemelrijck Journal: BMJ Open Date: 2022-04-04 Impact factor: 2.692